Kornimate/medical-research-clean huggingface dataset:
feasibility study of a belt applicator

Conditions: Body Fat Disorder

Summary: evaluate the safety and feasibility of non-invasive fat reduction in the outer thigh with a belt applicator. applicator design and treatment parameters will be evaluated.

the zeltiq coolsculpting system technology for cold-assisted lipolysis will be used with a modified belt applicator for the reduction of fat on the outer thigh. this is an open label, interventional, non-randomized feasibility study.

Eligibility criteria:
inclusion criteria * male or female subjects \> 18 years of age and \< 65 years of age. * subject has clearly visible fat on intended treatment area (outer thighs), which in the investigator's opinion, may benefit from the treatment(s). * subject has not had weight change exceeding 10 pounds in the preceding month. * subject with body mass index (bmi) up to 30. bmi is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. * subject agrees to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in his/her diet or lifestyle during the course of the study. * subject has read and signed a written informed consent form. exclusion criteria * subject has had a surgical procedure(s) in the area of intended treatment. * subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. * subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 6 months. * subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. * subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. * subject has a known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. * subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. * subject is taking or has taken diet pills or supplements within the past month. * subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). * subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system * subject is pregnant or intending to become pregnant in the next 8 months. * subject is lactating or has been lactating in the past 6 months. * subject is unable or unwilling to comply with the study requirements. * subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. * any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Keywords: lipolysis cryolipolysis fat reduction
miralax versus placebo to prevent constipation following urogynecologic surgery

Conditions: Post Procedural Constipation

Summary: a. purpose to compare miralax versus placebo for preventing constipation in the immediate postoperative period following pelvic reconstructive surgery in women taking routine docusate sodium. b. objectives 1. specific aims specific aim 1: to compare time to first bowel movement (bm) between miralax versus placebo in women receiving routine docusate sodium after pelvic reconstructive surgery. specific aim 2: to compare patient reported outcomes of bm quality and associated gastrointestinal (gi) symptoms between miralax versus placebo using the bristol stool scale and the validated patient assessment of constipation symptom questionnaire (pac-sym) in women receiving routine docusate sodium after pelvic reconstructive surgery. specific aim 3: to evaluate gi-related quality of life between miralax versus placebo utilizing the validated patient assessment of constipation quality-of-life questionnaire (pac-qol) in women receiving routine docusate sodium after pelvic reconstructive surgery. 2. hypotheses the investigators hypothesize that miralax will optimally prevent constipation following pelvic reconstructive surgery by decreasing time to first bm, decreasing gi symptoms associated with constipation, and increasing measures of gi-related quality of life, while minimizing the bothersome side effects associated with stimulant laxatives.

this is a randomized double-blind placebo-controlled clinical trial of miralax versus placebo in women undergoing pelvic reconstructive surgery receiving routine docusate sodium. subjects will be screened for eligibility during their preoperative visits and once enrolled, they will be randomized to receive miralax or placebo starting on postoperative day (pod) 1 and continuing through pod 5. subjects will be instructed to stop taking this medication if they experience any diarrhea. subjects in both arms will be instructed to take milk of magnesia as a rescue laxative if they do not experience a bm by the morning of pod 6. all subjects will be provided a 30 day supply of docusate sodium and be instructed to begin this medication on pod 1.

Eligibility criteria:
inclusion criteria: * english-speaking female patients * \> 18 years of age * not pregnant (patients of childbearing potential will have a serum pregnancy test done pre-operatively as part of their surgical planning) * undergoing surgery for pelvic organ prolapse or stress urinary incontinence * recruited from the duke university division of urogynecology exclusion criteria: * allergy/hypersensitivity to study medications * cardiac or renal disease * takes chronic daily laxatives * excluded if unable to complete at least 5 days of a 7 day baseline bowel diary * excluded if mesh resection or interstim procedure * excluded if concurrent surgery includes anal sphincteroplasty or rectovaginal fistula repair

Keywords: postoperative constipation urogynecologic surgery miralax docusate sodium
follow-up of recovery condition in survivors of acute respiratory distress syndrome

Conditions: Mortality

Summary: hope to realize the recovery condition of ards survivors in taiwan. it would be helpful not only to design the proper rehabilitation program but also to be a useful reference for the poor recovery patients to take hospice care if indicated.

this study will enroll the participant met the diagnostic criteria of ards. the basic data, clinical manifestations, laboratory data and outcomes of participants will be recorded. and the investigator will also follow up the pulse oximeter, peak expiratory flow rate, six-minute walk test and health-related quality of life measures with sf-36 in 3, 6 and 12 months after the participants were discharged from the icu. through this study, the investigator hope to realize the recovery condition of ards survivors in taiwan. it would be helpful not only to design the proper rehabilitation program but also to be a useful reference for the poor recovery patients to take hospice care if indicated.

Eligibility criteria:
inclusion criteria: * ards patients exclusion criteria: * na
an electronic brief alcohol intervention for women attending a breast screening service (health4her)

Conditions: Health Knowledge, Attitudes, Practice; Alcohol Drinking

Summary: alcohol is a major modifiable risk factor for female breast cancer; yet, awareness of this risk remains surprisingly low and is not systematically addressed in healthcare settings. this study aim to test the effectiveness of a co-designed, automated brief alcohol intervention (health4her-automated) in reducing women's drinking intentions, improving alcohol literacy, and reducing consumption.

alcohol is a major modifiable risk factor for female breast cancer, even in very low amounts. in australia, alcohol consumption accounts for 6.6 per cent of cases in post-menopausal women, and 18 per cent of breast cancer deaths. yet, awareness of this risk remains low and is not systematically addressed in healthcare settings. embedding a brief alcohol intervention within lifestyle information offered to all women attending breast screening provides the opportunity to address harmful drinking in a discrete, non-judgmental way, to prevent alcohol-attributable breast cancer among this at-risk population. brief alcohol interventions are short, single-session programs typically offered in general practice settings to gather information on a person's alcohol consumption and, in a non confrontational way, provide strategies and motivate change to reduce consumption and related risk of harm. an automated brief alcohol intervention, self-completed on a device such as an ipad, is a low-cost, labour- and time-efficient approach that overcomes many of the issues of providing intervention within busy healthcare environments. building on the previous pilot trial of a prototype brief e-health intervention (which included alcohol-related questions asked by a researcher, and an animation viewed on an ipad that was activated by the researcher), the aim of the current study is to test the effectiveness of a co-designed, automated brief alcohol intervention (health4her-automated) in reducing women's drinking intentions, improving alcohol literacy, and reducing consumption.

Eligibility criteria:
inclusion criteria: * female * 40+ years of age * attending routine breast screening * with or without a breast cancer history * reporting any level of alcohol consumption exclusion criteria: * not able to read or comprehend english to enable participation * no access to a computer, tablet or smartphone to complete follow-up assessment * women who are pregnant (also an exclusion from breast screening) * participation in the pilot health4her trial

Keywords: women's health public health health promotion
interscalene brachial plexus block to treat pain after clavicular surgery

Conditions: Acute Pain

Summary: the sensory innervation of the clavicle remains an area of debate. regional nerve blocks aimed at relieving pre- and post-operative pain include the superficial cervical plexus blocks, interscalene blocks and a combined version of the above. in this case study, the investigators aim to describe the protocol used in a university hospital: general anaesthesia with interscalene brachial plexus block, followed by optional iv morphine administration in phase 1 recovery and oral oxycodone on the ward.


Eligibility criteria:
inclusion criteria: * clavicular fracture with internal reduction * physical status i - iii exclusion criteria: * contraindication to regional anaesthesia * history of neck radiotherapy * patient suffering from chronic pain * severe respiratory disease

Keywords: clavicle
a comparison of prophylactic antibacterial efficacy of besivance vs. vigamox prior to cataract surgery

Conditions: Cataracts

Summary: to compare antibacterial efficacy of besivance versus vigamox for decreasing bacteria of the conjunctiva and lid margins in cataract patients prior to surgery after both 1 hour and 3 days of treatment.


Eligibility criteria:
inclusion criteria: * man or woman 18 years of age or older. * physically capable of instilling eye drop or have an appropriate person available to assist in administration of eye drops 4 times a day. * scheduled for phacoemulsification with intraocular lens (iol) implantation for the treatment of cataract. * meet the american society of anesthesiology (asa) physical status i, ii, or iii and be medically cleared for surgery. * willing to adhere to the prohibitions and restrictions specified in this protocol. * subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. exclusion criteria: * known allergy or contraindication to the test article(s) or their components. * presence of any abnormality or significant illness in the eye that in the investigator's opinion could affect the subject's health or the study parameters. * presence of an active ocular infection (bacterial, viral or fungal), or positive history of ocular herpetic infection. * history of any significant illness that could be expected to interfere with the study parameters. any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study. * use of disallowed therapies (systemic or topical): * fluoroquinolone anti-infective agents (systemic or topical) within 1 week of visit 1 or anytime after visit 1 for the duration of the study. * use of contact lenses for one week prior to the study and for the duration of the study. * received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment.
radiofrequency ablation followed by hepatic artery chemotherapy in treating patients with colorectal cancer that has spread to the liver

Conditions: Colorectal Cancer; Metastatic Cancer

Summary: rationale: radiofrequency ablation may be able to shrink or destroy cancer cells. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. chemotherapy delivered directly into the blood vessels of the liver may prevent new tumors from growing. combining these therapies may be an effective treatment for colorectal cancer that has spread to the liver. purpose: phase ii trial to study the effectiveness of radiofrequency ablation followed by chemotherapy delivered directly into the blood vessels of the liver in treating patients who have colorectal cancer that has spread to the liver.

objectives: i. determine the safety and efficacy of radiofrequency tissue ablation followed by hepatic arterial chemotherapy with floxuridine and fluorouracil in patients with colorectal cancer metastatic to the liver. outline: patients undergo an open laparotomy to identify the target tumor in the liver using intraoperative ultrasound followed by radiofrequency tissue ablation over 20 minutes to each tumor and placement of hepatic arterial catheter. within 35 days postoperatively, patients receive hepatic arterial chemotherapy consisting of floxuridine on days 1-7 and fluorouracil over 1 hour on days 15, 22, and 29. treatment repeats every 5 weeks for 6 courses. patients are followed at 1 month, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 42 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed colorectal cancer metastatic to the liver no preoperative or intraoperative evidence of extrahepatic metastasis including clinical, radiographic, gross or microscopic evidence tumors must be no more than 4 cm in diameter no more than 6 total tumors may have failed prior systemic chemotherapy failure of 1 prior intra-arterial regimen excluding floxuridine, fluorouracil, or another fluoropyrimidine allowed if liver enzymes recovered no evidence of cirrhosis no gross ascites patient characteristics: age: 18 and over performance status: zubrod 0-2 life expectancy: at least 16 weeks hematopoietic: granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl renal: creatinine no greater than 1.5 mg/dl or creatinine clearance at least 60 ml/min other: no active duodenal or gastric ulcers not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy (6-8 weeks since nitrosoureas or mitomycin) endocrine therapy: not specified radiotherapy: at least 4 weeks since prior radiotherapy no prior radiotherapy to the liver surgery: not specified

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer liver metastases
precision cell immunotherapy combined with tace in advanced liver cancer

Conditions: Precision Cell Immunotherapy; Transcatheter Arterial Chemoembolization; Advanced Liver Cancer

Summary: to evaluate the safety and effectiveness of cell therapy using precision cells combined with tace in advanced liver cancer. eligibility: individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with advanced liver cancer.

a total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility criteria:
inclusion criteria: 1. age 18\~65 years old, male or female; 2. life expectancy≥6 months; 3. ecog score: 0-3; 4. advanced malignancies (lung cancer, gastric cancer) were diagnosed by pathological or clinical physicians,and diagnosis of hepatocellular carcinoma (hcc), surgery can not be performed but tace treatment can be carried out; 5. enough venous channel, no other contraindications to the separation and collection of white blood cells; 6. laboratory examination: white blood cell≥3 x 10\*9/l, blood platelet count≥60 x 10\*/l, hemoglobin≥85g/l; lymphocyte count≥15%, total bilirubin≤100 mol/l; alt and ast less than five times of the normal level; serum creatinine less than 1.5 times of the normal level； 7. signed informed consent； 8. women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. exclusion criteria: 1. expected overall survival \< 3 months 2. the tumor size or quantity is not suitable for interventional treatment or portal vein tumor thrombus 3. liver function is childs pugh c 4. had received tace therapy previously or in radiotherapy at present,or taking sola feeney 5. other serious diseases:the heart,lung, kidney,digestive, nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc. 6. unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Keywords: precision cell immunotherapy transcatheter arterial chemoembolization advanced liver cancer
the effect of e-health video towards enhancing cervical cancer screening

Conditions: Cervical Cancer Screening

Summary: the aim of this quasi-experimental study is to evaluate the women's motivation related to cervical cancer screening. the experiment group will receive the e-health video kaseh and brochure as the intervention. where as, the control group will receive brochure as the intervention. there is three phase of evaluation which are pre-intervention, intra-intervention and post-intervention. the evaluation will be assess using the self-administered questionnaire based on protection motivation theory. the estimated duration of this quasi-experiment is six month.


Eligibility criteria:
inclusion criteria: * women who have never undergone cervical cancer screening. exclusion criteria: * women who have been diagnosed or are cervical cancer patients * women who have been diagnosed with any cancer of the gynecological system such as cancer of the vulva, vagina, uterus, fallopian tubes and ovaries.
cold water immersion and recovery

Conditions: Post-exercise Cold Water Immersion

Summary: cold-water immersion (cwi) is a frequently applied strategy to accelerate post-exercise recovery in both recreational as well as professional athletes. however, the effect of repeated post-exercise cwi on other recovery strategies remains unclear.


Eligibility criteria:
inclusion criteria: * males * aged between 18-35 years * healthy, recreationally active * bmi \< 25 kg/m2 * the ability to comply with the protocol (i.e. the set-up for the cwi is designed for subjects that are at least 1.70 m or taller). exclusion criteria: * smoking * allergies to milk proteins (whey or casein) * female * arthritic conditions * a history of neuromuscular problems * recent (\<1 y) participation in amino acid tracer studies * individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications). * individuals with gi diseases
dose escalated proton beam therapy or photon therapy for esophageal cancer

Conditions: Esophageal Cancer

Summary: this study will evaluate if proton beam therapy as part of chemoradiation results in a decrease in diffusion lung capacity of carbon monoxide (dlco) compared to photon radiation therapy for esophageal carcinoma. a secondary objective is to determine effects on cardiac function, quality of life, and compare acute and late toxicities.

radiation modality: proton radiotherapy will be offered to all patients that meet trial eligibility. if patients decline proton radiotherapy or are otherwise unable to receive proton therapy they will be included in x-ray cohort (group 2). chemotherapy will be delivered at the discretion of the treating medical oncologist. weekly carboplatin and paclitaxel at standard doses is preferred. it is recommended that the weekly chemotherapy regimen be continued throughout the course of radiotherapy. chemotherapy should begin within 48 hours of beginning radiotherapy.

Eligibility criteria:
inclusion criteria: * patient must be at least 18 years at the time of consent. * pathologically confirmed esophageal adenocarcinoma or squamous cell. carcinoma of the thoracic esophagus or esophagogastric junction. * patient's preliminary cancer stage, according to the ajcc 7th edition staging, must be ct1b-t4, n0-n3. exclusion criteria: * patients with cervical esophageal carcinoma. * prior radiotherapy with fields overlapping the current esophageal cancer. * patients with ct1a disease. * patients with evidence of tracheoesophageal fistula must undergo bronchoscopy to exclude fistula. * patients with distant metastatic disease.

Keywords: esophagus proton radiation